Hiroshi Igaki
Papers
1
Total Citations
6
H-Index
1
About
Hiroshi Igaki is a leading figure in radiation oncology, with a focused expertise in ultrahypofractionated radiation therapy for prostate cancer. His major contributions lie in the comparative analysis of high-dose-rate brachytherapy (HDR-BT) against robotic and conventional stereotactic body radiotherapy (SBRT), providing critical insights into treatment planning and dosimetry. His 2023 study, which systematically compares these modalities, has already garnered 6 citations, reflecting its immediate relevance to clinical decision-making. Igaki’s work is instrumental in optimizing treatment protocols, balancing efficacy with patient safety, and advancing precision in radiation delivery. Beyond this, his research informs the broader adoption of ultrahypofractionation, a rapidly evolving field that reduces treatment duration while maintaining tumor control. Igaki’s meticulous approach and clinical impact make him a valuable resource for students and researchers exploring the frontiers of prostate cancer radiotherapy, offering a benchmark for future studies in high-precision oncology.
Research Focus
Key Achievements
Top Papers
- 1